This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 1…

Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement

~Estimated

~$10 – $8,750

Taiho Oncology, Inc.NCT05727176

Phase 1

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.

Advanced CholangiocarcinomaFGFR2 Fusion

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06439485